KORU Medical Systems (KRMD) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $11.8 million, a 22% increase year-over-year.

Domestic Core Growth: 12% year-over-year, driven by new patient starts and competitive conversions.

International Core Growth: 35% year-over-year, supported by prefilled syringe conversions in Europe.

Gross Margin: 61.5%, slightly down from 62.8% in the prior year due to higher production costs and tariff-related charges.

Net Loss: Improved by 33% to $800,000.

Adjusted EBITDA: Essentially breakeven at -$10,000, a 95% improvement from the previous year.

Cash Position: Ended the quarter with $8.8 million, with minimal cash usage of $100,000.

2Strategic Updates and Business Highlights

Leadership Transition: CEO Linda Tharby announced her departure, with Adam Kalbermatten set to take over on July 1, 2026.

Three-Pillar Strategy: Focus on growing the domestic core business, international expansion, and adding more drugs to the Freedom Infusion System.

Pipeline Progress: Eight active non-Ig drug opportunities, with two collaborations advancing to Phase III clinical trials.

510(k) Application: Submitted for the Freedom Infusion System with deferoxamine, indicating ongoing commitment to expand beyond immunoglobulin (Ig) therapies.

Oncology Initiatives: Active discussions with pharmaceutical partners for new oncology assets, including the Phesgo submission currently under FDA review.

3Forward Guidance and Outlook

Full-Year 2026 Guidance: Revenue expected between $47.5 million and $50 million, representing 15% to 22% growth. Gross margin guidance remains at 61% to 63%, with positive adjusted EBITDA and cash flow anticipated for the year.

Market Dynamics: Anticipated revenue ramp-up in the second half of 2026, with a focus on new prefilled markets and patient adoption.

4Bad News, Challenges, or Points of Concern

Gross Margin Decline: A slight decrease in gross margin due to higher production costs and tariffs.

Geopolitical Risks: Caution regarding the Middle East market due to geopolitical instability, which may affect distributor orders.

Market Variability: Potential variability in international growth as the company transitions to a more active market conversion strategy rather than relying on pharma-driven tenders.

5Notable Q&A Insights

Revenue Guidance Rationale: Management maintained guidance despite a strong Q1, citing variability in market dynamics and the need to observe how new opportunities develop.

Oncology Pipeline: Discussions around the oncology market indicate a significant growth opportunity, with Phesgo expected to contribute approximately 1.1 million annual units.

Distributor Order Dynamics: Similar patterns to previous years are expected, with initial orders leading to increased adoption and subsequent orders in the latter half of the year.

Supply Chain Monitoring: The company is closely monitoring supply chain dynamics related to rising oil prices but has not yet seen material impacts. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a balanced view of KORU Medical Systems' current status and future outlook.